Related Experiment Video

Updated: Oct 8, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Converting enzyme inhibitors for the treatment of hypertension in the elderly

A C Pessina, E Casiglia

    International Journal of Clinical Pharmacology Research
    |January 1, 1986
    PubMed

    Insights

    High blood pressure poses risks for all ages. Captopril shows promise for treating hypertension in elderly patients, as it maintains vital blood flow and avoids dangerous drops in blood pressure.

    Area of Science:

    • Cardiology
    • Geriatrics
    • Pharmacology

    Background:

    • Epidemiological studies confirm hypertension's risk for cardiovascular morbidity and mortality across all age groups, including the elderly.
    • Treating hypertension in older adults presents challenges due to specific physiopathological characteristics.
    • Elderly patients often have reduced renal function, ischemic heart disease, cerebrovascular disease, and impaired baroreflex sensitivity.

    Purpose of the Study:

    • To evaluate the efficacy and tolerability of captopril in elderly hypertensive patients.
    • To assess captopril's suitability for treating hypertension in older individuals, considering their unique physiological conditions.

    Main Methods:

    • A captopril surveillance program was conducted.
    • Data from elderly hypertensive patients (over 60 years old) were analyzed.

    Main Results:

    • Captopril was found to be efficacious in treating hypertension in elderly patients.
    • Captopril was well-tolerated in this patient group.
    • Captopril does not reduce coronary, cerebral, and renal blood flow, and does not cause orthostatic hypotension.

    Conclusions:

    • Captopril is a potentially useful agent for managing hypertension in elderly patients.
    • The drug's properties make it suitable for older individuals with comorbidities like renal impairment and cardiovascular disease.
    • Further controlled studies are warranted, but initial surveillance data suggest captopril is a safe and effective option for geriatric hypertension.

    More Related Videos

    The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension05:57

    The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

    Published on: May 17, 2024

    Related Concept Videos

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Drug Dosing: Geriatric Patients01:15

    Drug Dosing: Geriatric Patients

    Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

    Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...